Universität zu Köln

Heydt, Carina, Ruesseler, Vanessa, Pappesch, Roberto, Wagener, Svenja, Haak, Anja, Siebolts, Udo, Riedel, Richard, Michels, Sebastian, Wolf, Juergen, Schultheis, Anne M., Rehker, Jan, Buettner, Reinhard and Merkelbach-Bruse, Sabine (2019). Comparison of in Situ and Extraction-Based Methods for the Detection of ROS1 Rearrangements in Solid Tumors. J. Mol. Diagn., 21 (6). S. 971 - 985. NEW YORK: ELSEVIER SCIENCE INC. ISSN 1943-7811

Full text not available from this repository.

Abstract

Clinical data confirmed that patients with ROS1 rearrangement are sensitive to specific inhibitors. Therefore, reliable detection of ROS1 rearrangements is essential. Several diagnostic techniques are currently available. However, previous studies were hampered by the low number of ROS1-positive samples. Thirty-five samples, including 32 ROS1 fluorescent in situ hybridization (FISH)-positive and three ROS1 FISH-negative samples were evaluated by ROS1 chromogenic in situ hybridization, ROS proto-oncogene 1, receptor tyrosine kinase (ROS1) immunohistochemistry (IHC), an Agilent SureSelect(XT) (HS) custom panel, the Archer FusionPlex Comprehensive Thyroid and Lung panel, and a custom NanoString fusion panel. Some samples were additionally analyzed with the Illumina TruSight Tumor 170 assay. Eleven samples were ROS1 FISH positive by a break-apart signal pattern. In all 11 samples, a ROS1 fusion was confirmed by at least one other method. The other 21 samples tested ROS1 FISH positive by an isolated 3' green signal pattern. Ten of 21 samples could be confirmed by at least two other methods. The other 11 samples tested negative by ROS1 IHC and at least one other method, indicating a false-positive ROS1 FISH result. Our study found that all ROS1 FISH-positive samples with isolated 3' green signals should be confirmed by another method. When sufficient material is available, extraction-based parallel sequencing approaches for the verification of these cases might be preferable.

Item Type:	Journal Article
Creators:	Creators Email ORCID ORCID Put Code Heydt, Carina UNSPECIFIED UNSPECIFIED UNSPECIFIED Ruesseler, Vanessa UNSPECIFIED UNSPECIFIED UNSPECIFIED Pappesch, Roberto UNSPECIFIED UNSPECIFIED UNSPECIFIED Wagener, Svenja UNSPECIFIED UNSPECIFIED UNSPECIFIED Haak, Anja UNSPECIFIED UNSPECIFIED UNSPECIFIED Siebolts, Udo UNSPECIFIED UNSPECIFIED UNSPECIFIED Riedel, Richard UNSPECIFIED UNSPECIFIED UNSPECIFIED Michels, Sebastian UNSPECIFIED UNSPECIFIED UNSPECIFIED Wolf, Juergen UNSPECIFIED UNSPECIFIED UNSPECIFIED Schultheis, Anne M. UNSPECIFIED UNSPECIFIED UNSPECIFIED Rehker, Jan UNSPECIFIED UNSPECIFIED UNSPECIFIED Buettner, Reinhard UNSPECIFIED UNSPECIFIED UNSPECIFIED Merkelbach-Bruse, Sabine UNSPECIFIED UNSPECIFIED UNSPECIFIED
URN:	urn:nbn:de:hbz:38-129248
DOI:	10.1016/j.jmoldx.2019.06.006
Journal or Publication Title:	J. Mol. Diagn.
Volume:	21
Number:	6
Page Range:	S. 971 - 985
Date:	2019
Publisher:	ELSEVIER SCIENCE INC
Place of Publication:	NEW YORK
ISSN:	1943-7811
Language:	English
Faculty:	Unspecified
Divisions:	Unspecified
Subjects:	no entry
Uncontrolled Keywords:	Keywords Language CELL LUNG-CANCER; ANAPLASTIC LYMPHOMA KINASE; FUSION VARIANT; IMMUNOHISTOCHEMISTRY; ADENOCARCINOMA; IDENTIFICATION; ALK; RET; VALIDATION; CRIZOTINIB Multiple languages Pathology Multiple languages
Refereed:	Yes
URI:	http://kups.ub.uni-koeln.de/id/eprint/12924